IBRX

$IBRX - Again a simple post Dr Pat . He just highlighted that Saudi FDA understood and accepted the data. Although it can be aeen3as a diss to FDA and maybe it is , it probably is , i just see it as a feel good piece or information. People correlate everything and there is a post on yahoo on how pss knows the q2 sales now and hoe he posted this on Saturday so that there will be a monday short squeeze. Nothjng will hapepen till ibrx gets more approvals. Those approvals cannot be foeced through tweets or please from ibrx shareholders . They will come but no matter how many pleas are done , only the decison makers have the say. Their hand cannot be forced . Pat is strategic . There are other fda too. So he may be pointing fingers . But who knows .

$IBRX

$IBRX Dr. Pat would not have made that X post if Anktiva with checkpoints in Saudi weren't doing well. NO WAY. What he's saying between the lines is that Anktiva is proving very successful in Saudi for lung cancer, if it weren't, he would look like an idiot highlighting the shortcoming of Keytruda or any other treatment. Very promising.

$IBRX Today, out of the blue and after months of relative silence, Dr. Pat cited a randomized NSCLC trial showing that continuing Keytruda with chemotherapy after progression did not improve survival. That's a very deliberate paper to highlight. His closing remark, "The Saudis got it right," made it even more interesting. To me, the message isn't about criticizing one drug—it's about acknowledging that when the current standard of care reaches its limits, patients deserve something better than more of the same. That's exactly why innovation matters. My opinion: you don't spotlight a study like this unless you're trying to start an important conversation or believe a better path exists. If that path is Anktiva and the next generation of immunotherapy, then I hope we're getting close. Patients who have exhausted today's options deserve another chance, and I believe that's the message Dr. Pat is trying to send.